CN101679496B - 用于由vwf前肽制备成熟vwf的方法 - Google Patents

用于由vwf前肽制备成熟vwf的方法 Download PDF

Info

Publication number
CN101679496B
CN101679496B CN2008800163745A CN200880016374A CN101679496B CN 101679496 B CN101679496 B CN 101679496B CN 2008800163745 A CN2008800163745 A CN 2008800163745A CN 200880016374 A CN200880016374 A CN 200880016374A CN 101679496 B CN101679496 B CN 101679496B
Authority
CN
China
Prior art keywords
vwf
furin
propetide
ripe
unit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2008800163745A
Other languages
English (en)
Chinese (zh)
Other versions
CN101679496A (zh
Inventor
沃尔夫冈·蒙特
阿图尔·米特雷尔
迈因哈特·哈斯拉赫尔
克丽斯塔·迈尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Publication of CN101679496A publication Critical patent/CN101679496A/zh
Application granted granted Critical
Publication of CN101679496B publication Critical patent/CN101679496B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN2008800163745A 2007-05-18 2008-05-16 用于由vwf前肽制备成熟vwf的方法 Active CN101679496B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93089107P 2007-05-18 2007-05-18
US60/930,891 2007-05-18
PCT/US2008/006291 WO2008143977A1 (en) 2007-05-18 2008-05-16 Method for producing mature vwf from vwf pro-peptide

Publications (2)

Publication Number Publication Date
CN101679496A CN101679496A (zh) 2010-03-24
CN101679496B true CN101679496B (zh) 2013-03-13

Family

ID=39666205

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008800163745A Active CN101679496B (zh) 2007-05-18 2008-05-16 用于由vwf前肽制备成熟vwf的方法

Country Status (16)

Country Link
US (1) US8058411B2 (enExample)
EP (1) EP2152735B1 (enExample)
JP (2) JP5053435B2 (enExample)
KR (1) KR101156263B1 (enExample)
CN (1) CN101679496B (enExample)
AU (1) AU2008254522B2 (enExample)
BR (1) BRPI0811649B8 (enExample)
CA (1) CA2684151A1 (enExample)
DK (1) DK2152735T3 (enExample)
ES (1) ES2539284T3 (enExample)
HU (1) HUE025257T2 (enExample)
MX (1) MX2009012387A (enExample)
NZ (1) NZ581582A (enExample)
PL (1) PL2152735T3 (enExample)
PT (1) PT2152735E (enExample)
WO (1) WO2008143977A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG191186A1 (en) * 2010-12-15 2013-07-31 Baxter Int Eluate collection using conductivity gradient
US20140276101A1 (en) * 2013-03-14 2014-09-18 Boston Scientific Scimed, Inc. Medical device for detecting a target and related methods of use
TWI666319B (zh) * 2014-08-12 2019-07-21 美商巴克斯歐塔公司 在分泌ｆｕｒｉｎ之哺乳動物表現系統中生產經完全加工且具功能性之因子Ｘ
CN111183151B (zh) 2017-06-23 2024-06-07 武田药品工业株式会社 因子viii亚种的纯化
MX2020009788A (es) * 2018-03-21 2020-12-09 Takeda Pharmaceuticals Co Separación de factor de von willebrand (vwf) y propéptido de factor de von willebrand (vwf) por métodos cromatográficos.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6210929B1 (en) * 1995-11-24 2001-04-03 Baxter Aktiengesellschaft Fusion protein comprising a furin derivative or a derivative of a furin analogue and a heterologous sequence

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT407750B (de) 1999-02-19 2001-05-25 Immuno Ag Verfahren zur herstellung einer vwf-präparation
KR20070092754A (ko) * 2004-12-27 2007-09-13 백스터 인터내셔널 인코포레이티드 중합체 - 폰 빌레브란트 인자 - 접합체

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6210929B1 (en) * 1995-11-24 2001-04-03 Baxter Aktiengesellschaft Fusion protein comprising a furin derivative or a derivative of a furin analogue and a heterologous sequence

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
B.E.Fischer 等.Recombinant von Willenbrand factor: potential therapeutic use..《Journal of thrombosis and thrombolysis》.1999,第8卷197-205. *
Fischer B E 等.Biochemical and functional characterization of recombinant von willebrand factor produced on a large scale.《CMLS CELLULAR AND MOLECULAR LIFE SCIENCES》.1997,第53卷943-950.
Fischer B E 等.Biochemical and functional characterization of recombinant von willebrand factor produced on a large scale.《CMLS CELLULAR AND MOLECULAR LIFE SCIENCES》.1997,第53卷943-950. *

Also Published As

Publication number Publication date
HK1144577A1 (en) 2011-02-25
AU2008254522A2 (en) 2010-02-18
EP2152735B1 (en) 2015-03-18
JP5053435B2 (ja) 2012-10-17
BRPI0811649A2 (pt) 2014-11-11
DK2152735T3 (en) 2015-04-20
CA2684151A1 (en) 2008-11-27
PL2152735T3 (pl) 2015-08-31
JP2010527588A (ja) 2010-08-19
US8058411B2 (en) 2011-11-15
EP2152735A1 (en) 2010-02-17
NZ581582A (en) 2012-02-24
HUE025257T2 (en) 2016-03-29
US20090029918A1 (en) 2009-01-29
JP2012210226A (ja) 2012-11-01
BRPI0811649B1 (pt) 2020-11-17
KR101156263B1 (ko) 2012-06-13
BRPI0811649B8 (pt) 2021-05-25
KR20100028042A (ko) 2010-03-11
MX2009012387A (es) 2010-02-10
AU2008254522A1 (en) 2008-11-27
WO2008143977A1 (en) 2008-11-27
ES2539284T3 (es) 2015-06-29
AU2008254522B2 (en) 2012-07-12
CN101679496A (zh) 2010-03-24
PT2152735E (pt) 2015-07-21

Similar Documents

Publication Publication Date Title
CN101679496B (zh) 用于由vwf前肽制备成熟vwf的方法
US12351843B2 (en) Method for purifying and quantifying thrombin and its degradation polypeptides
RU2544860C2 (ru) Очистка полипептидов
US20130115204A1 (en) Preparative purification process for human furin
JP2010527588A5 (enExample)
CN103814137A (zh) 处理凝血因子的方法
HK1144577B (en) Method for producing mature vwf from vwf pro-peptide
WO2016207328A1 (en) PROCESS FOR THE PURIFICATION OF γ-CARBOXYLATED POLYPEPTIDES
AU2012216707A1 (en) Method for Producing Mature VWF From VWF Pro-peptide
HK1145188B (en) Preparative purification process for human furin

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1144577

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1144577

Country of ref document: HK

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20160706

Address after: Aupu, Switzerland

Patentee after: Hundred deep limited liability company

Patentee after: Hundred deep company

Address before: Illinois

Patentee before: Baxter International Inc.

Patentee before: Bakst Helth Co., Ltd.

TR01 Transfer of patent right

Effective date of registration: 20210721

Address after: Osaka

Patentee after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: Aupu, Switzerland

Patentee before: BAXALTA GmbH

Patentee before: Baishen Co.

TR01 Transfer of patent right